Ibnsina Pharma
Fundamental — what it's worthbottom-up fair value
Built up from a discounted-cash-flow (FCFF) on the distribution business, a relative EV/EBITDA read, a normalized-earnings read and a dividend-yield floor — what is it worth?
Is it cheap or expensive right now?
Latest price vs our fair value. A comparison, not a recommendation.
What it's worth — four lenses
Four independent valuation methods, blended into one weighted central fair value.
| Valuation lens | Per share (EGP) | Weight |
|---|---|---|
| Discounted cash flow (FCFF) — primary | 19.79 | 45% |
| Relative — EV/EBITDA (trailing) | 16.71 | 25% |
| Normalized earnings power | 17.98 | 20% |
| Dividend / yield floor | 11.00 | 10% |
| Weighted central fair value | 17.78 | +52% vs spot |
The four lenses span EGP 11.0 (the dividend-yield floor) to EGP 19.8 (the DCF that capitalises the margin-and-scale story into a terminal value), centred on ~EGP 17.8 against the EGP 11.67 spot. Every lens sits above the price, and the whole distance is a bet on the net margin normalising as Egyptian interest rates ease and the drug-re-pricing cycle feeds through. The CBE rate path and the pace of re-pricing are the swing factors. Full detail is in the study and the open model. Note: for this name the §3 Monte-Carlo engine did not beat a random walk in the calibration back-test — the price map is illustrative only.
Technical & price structuretrend, momentum, key levels
Trend, momentum and key levels — what is the price doing now?
What the chart says
In plain terms: Ibnsina Pharma trades about 52% below our weighted central fair value — cheap on fundamentals, but priced for genuine Egyptian risk. A discounted-cash-flow on the distribution business lands near EGP 19.8 (the most optimistic lens, because it capitalises the margin-and-scale story into a terminal value), relative EV/EBITDA multiples near EGP 16.7 (the most grounded, anchored on what the market pays today for EBITDA), a normalized-earnings read near EGP 18.0, and a dividend-yield floor near EGP 11.0 — an EGP 11.0–19.8 cluster centred on ~EGP 17.8. Ibnsina Pharma is Egypt’s #1–2 pharmaceutical distributor: more than 35,000 customers, ~24% market share (IQVIA), revenue of EGP 76.6bn in FY25 at an ~8% gross and ~5% EBITDA margin, a ~1.2% net margin, and a near-zero cash-conversion cycle so growth is funded by suppliers rather than equity. The bull case (~EGP 22.7) is the net margin normalising as CBE rates ease and the drug-re-pricing cycle feeds through to margins; the cautious case (~EGP 12.9) is a razor-thin margin staying pinned by high finance costs and receivables risk. What moves it near-term is the CBE rate path, drug-re-pricing decisions, and each quarter’s margin print. One caveat specific to this name: in the calibration back-test the Monte-Carlo engine did not beat a simple random walk, so the 1–3-month price map below is illustrative of the method, not a reliable forecast for ISPH.
Key levels
Monte Carlo — where could the price go?near-term price paths
50,000 simulated futures — near-term price paths, independent of the fundamental value.
The 5th–95th and 25th–75th percentile bands from the 50,000-path simulation. Static and pre-computed — independent of the fundamental levers above.
The exact percentiles
The 5th / 25th / middle / 75th / 95th outcomesLine up all 50,000 outcomes low to high — these are the values at the 5%, 25%, 50%, 75% and 95% marks., from 50,000 paths.
| Timeframe | Rare low (5%) | 25% | Middle | 75% | Rare high (95%) |
|---|
What drives the odds
50,000 paths, 16 forces: seven continuous — Egyptian pharma-market volume, drug re-pricing / inflation pass-through, the CBE policy-rate path (the finance-cost driver), the EGP/USD rate, EGX30 & foreign flows, the working-capital / supplier-credit cycle, and market share vs competition — plus nine event forces: a quarterly results print, a CBE rate cut, a further re-pricing round, a new supplier / distribution deal, an EGP devaluation step, a drug shortage / disruption, a dividend / capital action, a receivables / credit event, and an index rebalancing. Zero secular drift for a name whose the calibration back-test failed. Details in the methodology.
Peer set & risks
Where Ibnsina Pharma sits in its market
Ibnsina Pharma is Egypt’s #1–2 pharmaceutical distributor — more than 35,000 customers and ~24% market share, distributing drugs, OTC, cosmetics and medical supplies from a national warehouse-and-delivery network. Its cleanest comparators are the other Egyptian distributors (largely private) and EM healthcare distributors; high local interest rates compress the multiples the market pays relative to global peers. This is a competitive map, not a price table.
| Arena | Ibnsina Pharma's position | Main peers |
|---|---|---|
| Egyptian pharma distribution | #1–2, ~24% share | UCP / Pharma Overseas (private) |
| Business model | Scale + working capital | vs smaller, credit-stretched peers |
| Cash-conversion cycle | ≈ 0 days (supplier-financed) | sector similar |
| Net margin | ~1.2% (rate-geared) | thin across the sector |
| EV/EBITDA (spot) | ~4.2× | EM distributors ~6–10× |
| Dividend yield | ~1.1% (payout ~17%) | reinvestment-focused |
The debate is normalisation, not quality — whether a scale-leading distributor with a near-zero cash-conversion cycle deserves better than ~4.2× EV/EBITDA once Egyptian rates ease and its thin net margin recovers. ISPH trades a deep discount to global healthcare distributors, but that gap is a fair Egyptian-risk discount — high finance costs on a levered balance sheet and receivables exposure — not a mispricing on its own. Competitive map, not advice.
About this series & how we build these
Want the full study and the spreadsheet?
Full write-up plus the editable Excel model.
Found a flaw? Attack the model
The full study (PDF) and Excel model are available on a computer.
Edition: 1 Jul 2026. Older editions stay in the Library.